Patents
Sitemap › A61 - Medical or veterinary science; Hygiene › A61K - Preparations for medical, dental, or toilet purposes › A61K 31 - Medicinal preparations containing organic active ingredients
Patents for A61K 31 - Medicinal preparations containing organic active ingredients (785,912)
03/2010
03/04/2010WO2010023422A1 Use of prebiotic galacto-oligosaccharides in the treatment of intestinal inflammation
03/04/2010WO2010023390A1 Use of an n-acyl amino acid selected from among n-palmitoyl alanine, n-palmitoyl glycine, and n-palmitoyl isoleucine as a regulating active agent of the genetic profile of senescent replicating fibroblasts of the human skin dermis
03/04/2010WO2010023375A1 Hexadecasaccharides with antithrombotic activity, including a covalent bond and an amino chain
03/04/2010WO2010023374A1 Polysaccharides with antithrombotic activity, including a covalent bond and an amino chain
03/04/2010WO2010023366A1 Rough lps as an immunostimulant in aquatic farming
03/04/2010WO2010023347A1 Anti-tumour compounds
03/04/2010WO2010023346A1 Hybrid tripyrrole-octaarginine compounds and their use as medicament in the treatment of cancer and microbial illnesses
03/04/2010WO2010023327A2 Method for obtaining oligonucleotide aptamers and uses thereof
03/04/2010WO2010023321A1 Liquid formulation containing a taxane derivative
03/04/2010WO2010023317A1 Novel hexafluoro-2-biphenylisopropanol compounds that modulate lxr-type receptors, process for the preparation thereof and use thereof as medicaments in human and veterinary medicine and also in cosmetics
03/04/2010WO2010023307A1 Novel urea and thiourea derivatives
03/04/2010WO2010023274A2 Composition for the treatment of alopecia
03/04/2010WO2010023218A1 Method and means for activating memory b lymphocytes
03/04/2010WO2010023197A2 Novel piperidine-4-acetamide derivatives and their use as monoamine neurotransmitter re-uptake inhibitors
03/04/2010WO2010023188A1 Pharmaceutical composition comprising n-[3-chloro-4-[(3- fluorophenyl)methoxy]phenyl]-6-[5[[[2-(methylsulfonyl)ethyl]amino]methyl]-2-furyl]-4- quinazolinamine
03/04/2010WO2010023187A1 Pharmaceutical composition comprising n-[3-chloro-4-[(3- fluorophenyl)methoxy]phenyl]-6-[5[[[2-(methylsulfonyl)ethyl]amino]methyl]-2-furyl]-4- quinazolinamine
03/04/2010WO2010023181A1 Thienopyrimidines for pharmaceutical compositions
03/04/2010WO2010023170A1 Dosage form comprising 1-isopropyl-4-{[4-(tetrahydro-2H-pyran- 4-yloxy)phenyl]carbonyl}hexahydro-1H-1,4-diazepine or a salt thereof
03/04/2010WO2010023162A1 Process for extraction of glucosinolate s from broccoli seeds
03/04/2010WO2010023161A1 Aryl- and heteroarylcarbonyl derivatives of substituted nortropanes, medicaments containing such compounds and their use
03/04/2010WO2010023065A1 Food supplement for the treatment of neuropathies
03/04/2010WO2010022988A1 N-(2-aminophenyl)-4-[n-(pyridine-3-yl)-methoxycarbonyl-aminomethyl]-benzamide (ms-275)polymorph b
03/04/2010WO2010022850A1 Fused pyrrolidino-cyclopropane derivatives as selective 11-beta-hydroxysteroid dehydrogenase type 1 inhibitors
03/04/2010WO2010022725A1 Pyridine derivatives as vegfr-2 receptor and protein tyrosine kinase inhibitors
03/04/2010WO2010022634A1 New ethylenediamine derivatives
03/04/2010WO2010022581A1 Medical composition for treating hyperuricemia and the use thereof
03/04/2010WO2010022580A1 Medical composition for treating hyperuricemia and the use thereof
03/04/2010WO2010022524A1 Emulsion preconcentrates, and micellar formulations comprising cyclodextrin
03/04/2010WO2010022497A1 Method of treating dysglycemia and glucose excursions
03/04/2010WO2010022467A1 Immunomodulating activities
03/04/2010WO2010022461A1 Sulphated sugars to increase activity of sulphatases en lysosomal storage disorders
03/04/2010WO2010022444A1 Methods and agents for modulating kinase signalling pathways through modulation of mixed-lineage kinase domain-like protein (mlkl)
03/04/2010WO2010022412A1 Octahydroquinolizines for antidiabetic treatment
03/04/2010WO2010009068A3 Cyclohexenyl modulators of chemokine receptor activity
03/04/2010WO2010007522A8 Rna antagonists targeting gli2
03/04/2010WO2010006111A3 Methods of using compositions comprising mir-192 and/or mir-215 for the treatment of cancer
03/04/2010WO2010005585A3 4-aminoquinazoline prodrugs
03/04/2010WO2010005581A4 Niacin compositions for reduction of amyloid beta peptide 42 (abeta 42) production and for treatment of alzheimer's disease (ad)
03/04/2010WO2010005520A3 Deuterated ibudilast
03/04/2010WO2010004231A3 Novel compounds, use thereof as medicaments, and method for the preparation thereof
03/04/2010WO2010004215A3 Substituted 1-benzyl-cinnolin-4(1h)-one derivatives, preparation thereof, and therapeutic use thereof
03/04/2010WO2010004198A3 Antineoplastic derivatives of 4-oxo-l, 4-dihydro-quinolinξ, preparation thereof, and therapeutic use thereof
03/04/2010WO2010000686A3 Composition for topical use comprising quinine
03/04/2010WO2009156951A3 5,6,7,8-tetrahydro-imidazo[1,5-a]pyrazine compounds
03/04/2010WO2009156860A3 4-(pyridin-4-yl)-1h-(1, 3, 5)triazin-2-one derivatives as gsk3-beta inhibitors for the treatment of neurodegenerative diseases
03/04/2010WO2009152597A3 Topical use composition for combatting ectoparasites in dogs and cats
03/04/2010WO2009152210A3 Coumarin compounds and their use for treating cancer
03/04/2010WO2009151712A3 Substituted phenylcyclohexylglycolates
03/04/2010WO2009150118A3 Novel salts of (4-{[(5-{[(3-chlorophenyl)methyl]oxy}-2-methylphenyl)carbonyl]amino}-3-methylphenyl)acetic acid
03/04/2010WO2009149955A3 Method for the selection of a suitable adjuvant for the production of solid dispersions for pharmaceutical formulations
03/04/2010WO2009149344A3 Solid states of aliskiren free base
03/04/2010WO2009149306A9 Complement depleting compounds and methods of treating cancer comprising monoclonal antibody therapy and said complement depleting compounds
03/04/2010WO2009148874A3 Gamma-lactam compounds for promoting bone growth
03/04/2010WO2009148620A3 Anthraquinones and analogs from rhuem palmatum for treatment of estrogen receptor beta-mediated conditions
03/04/2010WO2009148280A3 Diaryl hepatonoid-based compound useful as virus inhibitor
03/04/2010WO2009146887A3 Novel treatment of heart diseases
03/04/2010WO2009146131A3 Compositions for prevention/prophylactic treatment of poison ivy dermatitis
03/04/2010WO2009145591A3 Phenyl piperazine compounds, pharmaceutical composition including the same, and use thereof
03/04/2010WO2009145590A3 Phenyl piperazine compounds, pharmaceutical composition comprising the same, and use thereof
03/04/2010WO2009145557A3 Use of physcion-8-o-beta-d-glucopyranoside or physcion for promoting osteoblast activity
03/04/2010WO2009143454A3 Combination antitumor therapy
03/04/2010WO2009143292A9 Method of treating pneumoconiosis with oligodeoxynucleotides
03/04/2010WO2009143211A3 Salts of 2-fluoro-n-methyl-4-[7-(quinolin-6-yl-methyl)- imidazo[1,2-b][1,2,4]triazin-2-yl]benzamide and processes related to preparing the same
03/04/2010WO2009143078A9 Methods of treating brain cancer using hexose compounds
03/04/2010WO2009140676A3 Compositions and methods for inhibition of retroviruses
03/04/2010WO2009140572A3 Combinatorial treatment with glucose regulated protein-170 and melanoma differentiation associated gene-7
03/04/2010WO2009140553A3 Hypoxia activated drugs of nitrogen mustard alkylators
03/04/2010WO2009140432A3 Micelles for intracellular delivery of therapeutic agents
03/04/2010WO2009140225A3 Anti-inflammatory and immunosuppresive glucocorticoid steroids
03/04/2010WO2009140131A3 Compliant composites for application of drug-eluting coatings to tissue surfaces
03/04/2010WO2009138780A3 Combination of an egfr inhibitor with an endocrine agent and treatment of breast cancer
03/04/2010WO2009138601A3 Use of mannose-6-phosphate for controlling angiogenesis, ligament regeneration, and cartilage reconstruction
03/04/2010WO2009138437A4 Salicylate conjugates useful for treating metabolic disorders
03/04/2010WO2009138198A3 Compositions comprising hydroxytyrosol for the preventive and curative treatment of intestinal tract disorders
03/04/2010WO2009137471A3 Azo dye related small molecule modulators of protein-protein interactions
03/04/2010WO2009137378A3 Sequential administration of chemotherapeutic agents for treatment of cancer
03/04/2010WO2009135184A3 Methods for treating and/or preventing cardiomyopathies by erk or jnk inhibition
03/04/2010WO2009134877A3 Therapeutics for treatment resistant mental disorders
03/04/2010WO2009129491A3 Beta adrenergic receptor agonists for treatment of pain and/or inflammation
03/04/2010WO2009129147A4 Analgesic and anti-inflammatory compositions and methods for reducing, preventing or treating pain and inflammation
03/04/2010WO2009126835A3 Magnetic nanoparticle and method for imaging t cells
03/04/2010WO2009124950A3 4-methyl-4,5-dihydro-1h-pyrazole-3-carboxamide useful as a cannabinoid cb1 neutral antagonist
03/04/2010WO2009121033A3 Substituted nitrogen heterocycles and synthesis and uses thereof
03/04/2010WO2009120933A3 Pharmaceutical solutions and method for solubilizing therapeutic agents
03/04/2010WO2009120565A3 Novel prodrugs of c-17-heteroaryl steroidal cyp17 inhibitors/antiandrogens: synthesis, in vitro biological activities, pharmacokinetics and antitumor activity
03/04/2010WO2009120493A3 Stabilized compositions of alkylating agents and methods of using same
03/04/2010WO2009120489A3 Identifying medicinally active chemical entities in ethnobotanical substances
03/04/2010WO2009117515A3 Novel compounds advantageous in the treatment of central nervous system diseases and disorders
03/04/2010WO2009117283A3 Quinolizidinone m1 receptor positive allosteric modulators
03/04/2010WO2009114313A3 Methods for synthesizing antiviral compounds
03/04/2010WO2009111700A3 Oxadiazoanthracene compounds for the treatment of diabetes
03/04/2010WO2009111057A3 Fulvestrant formulations
03/04/2010WO2009087005A4 Composition comprising a nitrooxyderivative of acetaminophen and a anticonvulsant drug for the treatment of neuropathic pain
03/04/2010WO2009046294A3 Treatment of proliferative disorders using antibodies to psma
03/04/2010WO2009044392A3 Novel sirna structures
03/04/2010WO2009026257A9 Methods and compositions for controlling the bioavailability of poorly soluble drugs
03/04/2010WO2009025876A8 Crystalline forms of erlotinib hcl and formulations thereof
03/04/2010WO2009022327A3 Novel process for preparing highly pure levocetirizine and salts thereof
03/04/2010WO2009018188A3 Flea control method
03/04/2010WO2009010478A3 Use of piperidine derivatives as agonists of chemokine receptor activity
1 ... 2360 2361 2362 2363 2364 2365 2366 2367 2368 2369 2370 2371 2372 2373 2374 2375 2376 2377 2378 2379 2380 ... 7860